MTOR and acute lymphoblastic leukemia: Following the promising evidence of adding mTOR inhibitors to chemotherapy, the DFCI sponsored a multi-institutional phase 1b trial (NCT01523977) in first relapse pediatric ALL patients combining everolimus with a standard 4-drug reinduction regimen.